Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

BACKGROUND: Despite disappointing outcomes from immuno-monotherapy, studies reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy. Whether the response to prior EGFR-TKI has association with the outcomes of subsequent immunotherapy remains unclear. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sangtian, Wu, Fengying, Li, Xuefei, Zhao, Chao, Jia, Yijun, Jia, Keyi, Han, Ruoshuang, Qiao, Meng, Li, Wei, Yu, Jia, Zhou, Fei, Xiong, Anwen, Chen, Bin, Fan, Jue, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991800/
https://www.ncbi.nlm.nih.gov/pubmed/33777802
http://dx.doi.org/10.3389/fonc.2021.639947

Ejemplares similares

Ejemplares similares